Ten different drugs continued to kill cancer cells even when their target proteins were removed.
In the TITAN trial, health-related quality of life did not worsen with the addition of apalutamide to ADT versus placebo for patients with metastatic castration-sensitive prostate cancer.
Progression-free survival no different at five years when radiotherapy is used only if the cancer returns.
In mCRPC patients previously treated with docetaxel and either abiraterone or enzalutamide, third-line therapy with cabazitaxel offered longer imaging-based progression-free survival and overall survival compared with switching patients to the other antiandrogen, the CARD study found.
In a secondary analysis of NRG Oncology/RTOG 9601, some patients had no survival benefit from long-term antiandrogen treatment.